E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Bioprospecting of Marine Microorganisms"

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: 31 August 2018

Special Issue Editor

Guest Editor
Prof. Usama Ramadan Abdelmohsen

Department of Pharmacognosy, Faculty of Pharmacy, Minia University, Minia, Egypt
Website | E-Mail
Phone: 0049-931-3180297
Interests: marine sponges; marine actinomycetes; natural products; medicinal plants; peptides; metabolomics

Special Issue Information

Dear Colleagues,

Microorganisms are leading sources of novel compounds that have been used in the pharmaceutical industry since their discovery. Several bacterial and fungal classes are capable of synthesizing various classes of secondary metabolites. The diversity in their chemical structures (alkaloids, polyketides, peptides and terpenes), as well as their bioactivities (antifungal, antibacterial, antiviral, antiparasitic, immunomodulatory, antioxidant, anti-inflammatory, and anticancer) highlight their role in pharmaceutical and agricultural research. Since the discovery of penicillin in 1928, several microorganism-derived antibiotics have been discovered and the recent example is teixobactin. Teixobactin was identified by Ling and coworkers from a soil microorganism (provisionally named Eleftheria terrae) and represent a new class of antibiotics. The presence in those extreme environmental conditions, such as high pressure, lack of light, salinity and pH, provoke marine microorganisms to biosynthesize a unique variety of chemicals, of which a large number are still unexplored in comparison to their terrestrial counterparts, and can become a source of bioactive lead compounds.

This Special Issue “Bioprospecting of Marine Microorganisms” in Marine Drugs will cover the scope of natural products derived from marine microorganisms. Phylogenetic and diversity studies as well as new methodologies for isolating marine microorganisms will also be targeted in this Special Issue.

As Guest Editor, I encourage all researchers who are interested in marine research to contribute their latest research findings in this area. I hope that it will help to gain more knowledge about marine microorganisms as a leading source for drug discovery.

Prof. Usama Ramadan Abdelmohsen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Marine microorganisms
  • Natural products
  • Bioactivities
  • Marine actinomycetes
  • Marine fungi
  • Drug discovery
  • İsolation
  • Structure elucidation

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessArticle Isolation of Petrocidin A, a New Cytotoxic Cyclic Dipeptide from the Marine Sponge-Derived Bacterium Streptomyces sp. SBT348
Mar. Drugs 2017, 15(12), 383; doi:10.3390/md15120383
Received: 25 October 2017 / Revised: 6 November 2017 / Accepted: 16 November 2017 / Published: 6 December 2017
PDF Full-text (560 KB) | HTML Full-text | XML Full-text
A new cyclic dipeptide, petrocidin A (1), along with three known compounds—2,3-dihydroxybenzoic acid (2), 2,3-dihydroxybenzamide (3), and maltol (4)—were isolated from the solid culture of Streptomyces sp. SBT348. The strain Streptomyces sp. SBT348 had been
[...] Read more.
A new cyclic dipeptide, petrocidin A (1), along with three known compounds—2,3-dihydroxybenzoic acid (2), 2,3-dihydroxybenzamide (3), and maltol (4)—were isolated from the solid culture of Streptomyces sp. SBT348. The strain Streptomyces sp. SBT348 had been prioritized in a strain collection of 64 sponge-associated actinomycetes based on its distinct metabolomic profile using liquid chromatography/high-resolution mass spectrometry (LC-HRMS) and nuclear magnetic resonance (NMR). The absolute configuration of all α-amino acids was determined by HPLC analysis after derivatization with Marfey’s reagent and comparison with commercially available reference amino acids. Structure elucidation was pursued in the presented study by mass spectrometry and NMR spectral data. Petrocidin A (1) and 2,3-dihydroxybenzamide (3) exhibited significant cytotoxicity towards the human promyelocytic HL-60 and the human colon adenocarcinoma HT-29 cell lines. These results demonstrated the potential of sponge-associated actinomycetes for the discovery of novel and pharmacologically active natural products. Full article
(This article belongs to the Special Issue Bioprospecting of Marine Microorganisms)

Back to Top